Compare IDEXX Laboratories, Inc. (IDXX) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares Core MSCI Emerging Markets ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares Core MSCI Emerging Markets ETF trades at $81.35 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 4× IDEXX Laboratories, Inc.'s market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| IDXX | IEMG | |
|---|---|---|
Market Cap | $40.43B | $162.00B |
Volume | 692,164 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $86.00 |
52-Week Low | $504.70 | $64.22 |
Typical Hold Time | 46 Days | 57 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
